文献速递免疫规划妇幼与学校卫生

住院早产儿及时接种尼塞韦单抗的安全性

Safety of timely immunization with nirsevimab in hospitalized preterm infants.
PubMed 文献 · Vaccine · 2025-08-15

本研究为观察性、非对照、前瞻性研究,纳入临床稳定的住院早产儿110例,其中103例(93.5%)接种尼塞韦单抗,中位胎龄33周、出生体重1892克,接种中位日龄3天;未报告过敏反应、惊厥或局部不良事件,16.5%出现全身不良事件,发热多为轻度,8.7%发生呼吸暂停且主要见于胎龄较低者,作者推荐在呼吸道合胞病毒流行季对住院早产儿早期监测下接种。

要点

  • 住院早产儿尼塞韦单抗接种率93.5%(103/110),中位接种日龄3天。
  • 未报告过敏反应、惊厥或局部不良事件,16.5%出现全身不良事件,发热多为轻度。
  • 8.7%发生呼吸暂停,主要见于胎龄<32周者,多数经触觉刺激恢复。

核心结论

  • 尼塞韦单抗接种无论胎龄或出生体重均安全,呼吸暂停主要见于胎龄<32周者,作者推荐在呼吸道合胞病毒流行季对住院早产儿早期监测下接种。

研究设计与样本

  • 观察性、非对照、前瞻性研究,纳入新生儿病房临床稳定的早产儿110例,其中103例接种尼塞韦单抗。

主要发现

  • 接种率93.5%(n=103),中位胎龄33周、中位出生体重1892克,接种中位日龄3天。
  • 未报告过敏反应、惊厥或局部不良事件;16.5%(n=16)报告全身不良事件。
  • 发热(n=8)为轻度,中位38°C;8.7%(n=9)发生呼吸暂停,中位发生于接种后26小时,主要见于胎龄较低者。
  • 呼吸暂停者中8例经触觉刺激恢复,1例需插管但与尼塞韦单抗注射无关;心动过缓仅2例发生于呼吸暂停期间,均经触觉刺激完全恢复。

临床怎么用

  • 作者推荐在呼吸道合胞病毒流行季对住院早产儿早期监测下接种尼塞韦单抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to assess the safety profile of nirsevimab in hospitalized preterm infants (PT). We conducted an observational, uncontrolled, prospective study in clinically stable PT admitted to the neonatal unit. One hundred and ten PT were eligible for immunization; uptake was 93.5 % (n = 103) (median GA and BW of 33 weeks and 1892 g, respectively), and a median age at immunization of 3 days. No anaphylaxis, seizures or local AE were reported. 16.5 % (n = 16) reported systemic AEs. Fever (n = 8) was mild (median of 38 °C). 8.7 % (n = 9) experienced apneas (median of 26 h post-immunization), mainly in PT with lower GA. Eight recovered with tactile stimulation, and one required intubation which was unrelated to nirsevimab injection. Bradycardia occurred only in two PT during apneic episodes, being both fully recovered with tactile stimulation. Nirsevimab administration was safe regardless GA or BW, with apnea reported mainly in those <32 weeks. Therefore, we recommend early and monitored administration of nirsevimab in hospitalized PT during RSV season.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Izquierdo G, Villena R, Cabrera C, et al. Safety of timely immunization with nirsevimab in hospitalized preterm infants. Vaccine. 2025. PMID: 40818313. doi:10.1016/j.vaccine.2025.127591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。